ABUS icon

Arbutus Biopharma
ABUS

Overview Fund Activity

118 hedge funds and large institutions have $131M invested in Arbutus Biopharma in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 39 increasing their positions, 35 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
118
Holders Change
-4
Holders Change %
-3.28%
% of All Funds
1.87%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
17
Increased
39
Reduced
35
Closed
20
Calls
$5.7M
Puts
$6.99M
Net Calls
-$1.29M
Net Calls Change
-$6.21M

Top Buyers

1
Hudson Bay Capital Management
1
Hudson Bay Capital Management
Connecticut
$13.4M
2
Assenagon Asset Management
2
Assenagon Asset Management
Luxembourg
$6.32M
3
TSC
3
Two Seas Capital
New York
$6.55M
4
BC
4
Brookfield Corp
Ontario, Canada
$6.94M
5
Goldman Sachs
5
Goldman Sachs
New York
$4.59M

Top Sellers

1
RI
1
RTW Investments
New York
$0
2
Millennium Management
2
Millennium Management
New York
$6.01M
3
GPP
3
Great Point Partners
Connecticut
$0
4
Two Sigma Investments
4
Two Sigma Investments
New York
$355K
5
Bank of America
5
Bank of America
North Carolina
$143K
Name Holding Trade Value Shares
Change 		Shares
Change %
TCM
126
Traynor Capital Management
Pennsylvania
– -$42K -11,000 Closed
QC
127
QCM Cayman
Texas
– -$40K -10,205 Closed
SAM
128
Secure Asset Management
Michigan
– -$39K -10,000 Closed
Bank Julius Baer & Co
129
Bank Julius Baer & Co
Switzerland
– -$30K -7,800 Closed
GWM
130
Geneos Wealth Management
Colorado
– -$3K -1,000 Closed
TWC
131
TD Waterhouse Canada
Ontario, Canada
– -$3.35K -900 Closed
MTWM
132
Masso Torrence Wealth Management
New Jersey
– -$2K -500 Closed
US Bancorp
133
US Bancorp
Minnesota
– -$2K -475 Closed
2 3 4 5
6